Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity

Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer. However, it requires repetitive systemic administration of high mAbs doses, often leading to adverse effects. We generated a novel nanobody ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Pilipich, Noelia, Martisova, Eva, Ballesteros-Briones, María Cristina, Hervas-Stubbs, Sandra, Casares, Noelia, González-Sapienza, Gualberto, Smerdou, Cristian, Vanrell, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761623/
https://www.ncbi.nlm.nih.gov/pubmed/33276580
http://dx.doi.org/10.3390/biomedicines8120562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761623/
https://www.ncbi.nlm.nih.gov/pubmed/33276580
http://dx.doi.org/10.3390/biomedicines8120562

Ejemplares similares